| NCT06419374 | A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | RECRUITING | PHASE3 | 2024-05-24 | 2031-08 | 2028-06 |
| NCT06318169 | A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | RECRUITING | PHASE3 | 2024-03-13 | 2029-02 | 2029-02 |
| NCT05852431 | To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-06-15 | 2026-04 | 2025-07-07 |
| NCT05022693 | PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis | COMPLETED | PHASE1 | 2021-08-16 | 2021-12-21 | 2021-12-21 |
| NCT04929483 | Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH) | COMPLETED | PHASE2 | 2021-06-04 | 2024-10-08 | 2023-02-14 |
| NCT04541186 | Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia | COMPLETED | PHASE2 | 2020-09-01 | 2022-05-31 | 2022-05-19 |
| NCT04048135 | A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH | COMPLETED | PHASE1, PHASE2 | 2019-07-29 | 2022-01-19 | 2020-08-28 |